Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BeiGene, Ltd. (ONC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: ONC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 4.51% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 28.48B USD | Price to earnings Ratio - | 1Y Target Price 331.74 |
Price to earnings Ratio - | 1Y Target Price 331.74 | ||
Volume (30-day avg) 556269 | Beta 0.65 | 52 Weeks Range 126.97 - 287.88 | Updated Date 03/27/2025 |
52 Weeks Range 126.97 - 287.88 | Updated Date 03/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.12 |
Earnings Date
Report Date 2025-02-27 | When - | Estimate -1.0175 | Actual -1.43 |
Profitability
Profit Margin -16.92% | Operating Margin (TTM) -6.31% |
Management Effectiveness
Return on Assets (TTM) -6.07% | Return on Equity (TTM) -18.77% |
Valuation
Trailing PE - | Forward PE 204.08 | Enterprise Value 26930518296 | Price to Sales(TTM) 7.47 |
Enterprise Value 26930518296 | Price to Sales(TTM) 7.47 | ||
Enterprise Value to Revenue 7.07 | Enterprise Value to EBITDA - | Shares Outstanding 98684704 | Shares Floating 958920813 |
Shares Outstanding 98684704 | Shares Floating 958920813 | ||
Percent Insiders 19.24 | Percent Institutions 42.52 |
Analyst Ratings
Rating 4.48 | Target Price 280.92 | Buy 7 | Strong Buy 12 |
Buy 7 | Strong Buy 12 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
BeiGene, Ltd.
Company Overview
History and Background
BeiGene, Ltd. was founded in 2010 as a biotechnology company focused on developing and commercializing innovative oncology medications. It has grown from a research-focused startup to a global company with operations in multiple countries and a portfolio of approved and investigational drugs.
Core Business Areas
- Research and Development: Focused on discovering and developing novel cancer therapies, utilizing its internal research capabilities and collaborations.
- Commercialization: Marketing and selling its approved drugs in various markets, including the United States, China, and Europe.
- Manufacturing: Manufacturing capabilities to produce its own drugs and manage the supply chain effectively.
Leadership and Structure
BeiGene is led by a team of experienced executives in the pharmaceutical and biotechnology industries. The organizational structure includes research, development, commercial, and manufacturing departments, reflecting its integrated business model.
Top Products and Market Share
Key Offerings
- Brukinsa (zanubrutinib): A BTK inhibitor approved for various hematological malignancies. It competes with Imbruvica (ibrutinib) and Calquence (acalabrutinib). While precise market share data is dynamic, Brukinsa is gaining traction in the BTK inhibitor market. Revenue has steadily increased, surpassing $1 billion in 2023. Competitors include AbbVie and AstraZeneca.
- Tislelizumab: A PD-1 inhibitor approved in China for various solid tumors. Competition includes other PD-1 inhibitors from companies like Merck (Keytruda) and Bristol Myers Squibb (Opdivo). Tislelizumab holds a significant market share in China, but its global presence is still developing. Market share data is region-specific and varies. Competitors include Merck and Bristol Myers Squibb.
Market Dynamics
Industry Overview
The oncology drug market is characterized by high growth, intense competition, and rapid innovation. There is a strong demand for novel therapies with improved efficacy and safety profiles. Increasing cancer incidence and aging populations drive market expansion.
Positioning
BeiGene is positioned as a global biotechnology company focused on developing innovative and affordable cancer medicines. Its competitive advantage lies in its strong research capabilities, global presence, and commitment to addressing unmet medical needs in oncology.
Total Addressable Market (TAM)
The global oncology drug market is projected to reach $300 billion+ by 2028. BeiGene is positioned to capture a significant portion of this TAM through its portfolio of approved and investigational drugs, as well as through strategic collaborations.
Upturn SWOT Analysis
Strengths
- Innovative oncology pipeline
- Global presence with operations in key markets
- Strong research and development capabilities
- Experienced management team
- Growing commercial infrastructure
Weaknesses
- Reliance on a few key products
- Limited profitability
- Dependence on partnerships for certain markets
- Competition from established pharmaceutical companies
Opportunities
- Expanding into new markets
- Acquiring or licensing complementary technologies
- Developing new indications for existing drugs
- Forging strategic collaborations to accelerate drug development
- Increasing demand for biosimilars in the China market
Threats
- Regulatory challenges and delays
- Competition from biosimilars and generics
- Unfavorable pricing and reimbursement policies
- Clinical trial failures
- Economic downturns impacting healthcare spending
Competitors and Market Share
Key Competitors
- ABBV
- AZN
- MRK
- BMY
Competitive Landscape
BeiGene faces intense competition from established pharmaceutical companies with larger resources and broader portfolios. Its competitive advantage lies in its innovative pipeline and focus on developing affordable cancer medicines.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: BeiGene has experienced rapid growth in revenue and R&D investment over the past decade.
Future Projections: Analysts project continued revenue growth for BeiGene as its approved drugs gain market share and new products are launched. Profitability is expected to improve over time.
Recent Initiatives: Recent initiatives include expanding its commercial infrastructure in key markets, advancing its pipeline of investigational drugs, and forging strategic partnerships.
Summary
BeiGene is a promising biotechnology company with a growing portfolio of oncology drugs and a strong research pipeline. While the company has yet to achieve sustained profitability, its revenue growth and commitment to innovation are encouraging. BeiGene faces significant competition from established pharmaceutical companies but is well-positioned to capitalize on the growing demand for novel cancer therapies. Key areas to watch include regulatory approvals, clinical trial results, and market share gains for its key products.
Similar Companies
- ABBV
- AZN
- MRK
- BMY
- GILD
Sources and Disclaimers
Data Sources:
- Company filings, Analyst reports, Industry publications, Market research reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market data and projections are subject to change and may not be accurate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BeiGene, Ltd.
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2016-02-03 | Co-Founder, Executive Chairman & CEO Mr. John V. Oyler | ||
Sector Healthcare | Industry Biotechnology | Full time employees 11000 | Website https://www.beigene.com |
Full time employees 11000 | Website https://www.beigene.com | ||
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; Ociperlimab (BGB-A1217), a TIGIT inhibitor; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.